Vepalimomab

Vepalimomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	VAP-1
Clinical data
ATC code	none;
Identifiers
CAS Number	195158-85-1 ;
ChemSpider	none;
(what is this?) (verify)

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1.[1] Development of the drug was discontinued in 2002.[2]

References

Vainio, PJ; Kortekangas-Savolainen, O; Mikkola, JH; Jaakkola, K; Kalimo, K; Jalkanen, S; Veromaa, T (2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.
"Vepalimomab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Vainio, PJ; Kortekangas-Savolainen, O; Mikkola, JH; Jaakkola, K; Kalimo, K; Jalkanen, S; Veromaa, T (2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.

[2] "Vepalimomab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.